Electrical Storm by Federico Guerra et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
18 
Electrical Storm 
Federico Guerra, Matilda Shkoza, Marco Flori and Alessandro Capucci 
Cardiology Clinic, Marche Polytechnic University 
Italy 
1. Introduction   
Electrical storm (ES) is usually defined as a clustering of destabilizing episodes of 
ventricular tachycardia or ventricular fibrillation in a short period of time, requiring 
multiple cardioversions or defibrillations. Many criteria have been proposed to define ES 
since the early 1990s, when the term was first introduced to indicate a state of electrical 
instability with several ventricular tachycardias (VT) or ventricular fibrillations (VF) over a 
few hours. At present an official and widespread definition of ES is not available. ES has 
been defined differently, from two or more to twenty or more episodes within 24 hours. 
Some definitions were based on number of hemodynamically unstabilizing episodes, others 
relied on number of shocks needed (or just delivered, whether appropriate or not), and 
some others on time between each single episode. More imaginative definitions include “VT 
recurring immediately after termination”, “VT for an half  of each of three days” and “VT 
resulting in more total ventricular ectopic beats than sinus beats in 24 hours” (Israel et al, 
2007). Fortunately, nowadays most cardiologists define ES as recurrent VT or VF, at least 3 
in a 24 hours period, as this is probably the most appropriate and solid definition. This 
definition does not include the presence of haemodynamic instability, since the intervention 
of modern implanted cardioverter-defibrillator (ICD) usually terminates the arrhythmia 
before its clinical and hemodynamical consequences. 
Similarly to definitions, many names have been used as synonymous to ES, such as 
arrhythmic storm, recurrent short-term ventricular arrhythmia, VT clusters and electrical 
instability. In this chapter we will use the term ES, as the most used and widespread in 
clinical practice. 
ES is more frequently seen as an acute complication of myocardial infarction, as a not-so-
uncommon adverse event in ischemic and non ischemic dilated cardiomyopathy and in 
genetic arrhythmia syndromes, such as congenital long QT syndrome and Brugada 
syndrome. However, the highest incidence of ES is reported in heart failure patients with 
ICD. This incidence, which ranges from 4% to 60% according to different studies, is mainly 
due to two factors. First, ICD can detect the VT of VF underlying a clinical episode of 
dizziness, syncope or even aborted sudden cardiac death, thus making the diagnosis far 
easier. Second, and most important, it can effectively treat the first and second VT or VF, 
thus saving the patient from sudden cardiac death and making him able to withstand more 
arrhythmic episodes. 
The current chapter will summarize the current epidemiology and diagnosis of electrical 
storm, as well as give some insight on current recommendation regarding pharmacological 
and non pharmacological treatment. 
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2. Epidemiology of electrical storm 
2.1 Incidence of electrical storm and its different causative arrhythmias 
In the last twenty years, several studies were carried out to determine the incidence of ES 
(table 1). 
 
 
 
Author Year Definition Population % 
Wood 1995 ≥3 VT/VF ≤24 h ICD (secondary prevention) 10 
Kowey 1996 ≥2 VT/VF ≤24 h All ES patients - 
Villacastin 1996 ≥2 shocks for VT ICD (secondary prevention) 20 
Fries 1997 >2 VT ≤ 1 h ICD (secondary prevention) 60 
Credner 1998 ≥3 VT/VF ≤24 h ICD (secondary prevention) 10 
Nademanee 2000 
≥20 VT/VF ≤24 h 
≥4 VT/VF ≤1 h All ES patients - 
Greene 2000 ≥3 VT/VF ≤24 h ICD (secondary prevention) 18 
Bansch 2000 ≥3 VT/VF ≤24 h ICD (secondary prevention) 28 
Exner 2001 ≥3 VT/VF ≤24 h ICD (secondary prevention) 20 
Verma 2004 ≥2 VT/VF ≤24 h ICD (secondary prevention) 10 
Arya 2005 ≥3 VT/VF ≤24 h ICD (30% primary prevention) 13 
Brigadeau 2006 ≥2 VT/VF  ≤24 h ICD (secondary prevention) 58 
Honhloser 2006 ≥3 VT/VF ≤24 h ICD (secondary prevention) 23 
Sesselberg 2007 ≥3 VT/VF ≤24 h ICD (primary prevention) 4 
Nordbeck 2010 ≥3 VT/VF ≤24 h ICD (55% primary prevention) 7 
Streinert 2011 ≥3 VT/VF ≤24 h ICD (81% primary prevention) 7 
Table 1. Incidence of electrical storm according to different definitions and populations. 
However, due to different definitions of ES and different populations, results vary widely. 
Most of the evidences come from ICD populations implanted after sustained ventricular 
arrhythmias, in which ES incidence ranges from 10 to 60 %. ICD recipients implanted for 
primary prevention, either with underlying ischemic or idiopathic dilated cardiomyopathy, 
have a lower incidence of ES (from 4 to 7%). 
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Little is known about incidence after acute myocardial injury, except that is more common 
in acute ST-elevation myocardial infarction (STEMI), when STEMI is associated with an 
important left ventricular dysfunction and when reperfusion therapy (either fibrinolysis or 
percutaneous angioplasty) is late or ineffective. 
Similarly, exact incidence and prevalence of ES in genetic arrhythmic syndromes such as 
Brugada syndrome, familiar long QT syndrome, short-coupled variant of torsade de pointes 
and right ventricular arrhytmogenic cardiomyopathy is still unknown. Albeit they are all 
rare conditions, patients afflicted by genetic arrhythmic syndromes are tipically young and 
otherwise healthy subjects, therefore in immediate need for ES primary prevention. 
More than 8 out of 10 arrhythmic episodes constituting ES are monomorphic VT (mVT), 
with polymorphic VT (pVT) and VF far behind in prevalence (Table 2). 
 
 
Author Year mVT (%) pVT+VF (%) 
Credner 1998 71 29 
Greene 2000 97 3 
Bansch 2000 91 8 
Exner 2001 86 14 
Verma 2004 52 48 
Brigadeau 2006 90 10 
Honhloser 2006 91 9 
Sesselberg 2007 78 22 
Nordbeck 2010 85 15 
Streinert 2011 73 27 
Table 2. Prevalence of different ventricular arrhythmia types in ES. 
Sustained monomorphic VT is usually related to structural heart disease. Monomorphic VT 
self-propagation is made possible by a reentry mechanism around a fixed anatomic barrier, 
which is often represented by a myocardial scar from a previous MI. The same ischemic 
cardiomyopathy, as it progresses, leads to fibrosis which in turn leads to conduction 
slowdowns, creating the perfect pathway for reentrant VT. In this particular setting an 
otherwise harmless trigger such as a premature ventricular contraction is necessary to start 
monomorphic VT. Monomorphic reentrant VT does not require active ischemia as a trigger, 
and is an uncommon cause of ES in acute myocardial infarction. 
VF and pVT are due to different mechanisms, comprehending multiple activation of 
different ventricular foci (pVT) or chaotic activation of the whole endocardial ventricular 
surface (VF). These two arrhythmias are more common in acute myocardial infraction or 
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when a long QT interval is present. Therefore QT interval should be assessed in all 
patients with ES due to pVT or VF as soon as sinus rhythm has been restored. Acquired 
causes of long QT, such as hypokalemia, hypocalcemia, hypomagnesemia, 
hypothyroidism and medication known to prolong QT interval, should be corrected as 
soon as possible. Inherited causes of long QT should be suspected whether an acquired 
cause cannot be found. 
2.2 Short and long-term prognosis of electrical storm 
Available data strongly suggest that patients who experience an ES have a poor outcome. 
Only a few trials were inconclusive regarding the role of ES as a mortality marker, and those 
usually had a wider definition of ES or a shorter follow-up. In secondary prevention 
populations such as the one of the AVID trial (Exner et al, 2001), patients with ES had a 
higher risk for non-sudden cardiac death (OR 2.4). In a substudy of the MADIT-II trial, 
which enrolled primary prevention patients, the risk of death was even higher (OR 7.4). 
Consistent findings suggest that the increase in mortality is mainly due to the worsening of 
ventricular dysfunction leading to end stage heart failure, with only a small proportion of 
sudden cardiac or other deaths (Gatzoulis et al, 2005). This hypothesis is also supported by 
the fact that risk of death after ES reaches its peak around 2-3 months after the acute event. 
Another main clinical consequence of ES is hospitalization, which is required for a proper 
treatment in approximately 80% of patients (Bänsch et al, 2000). Hospitalization rates grow 
higher with each shock delivered, reaching 100% if 3 or more shocks are needed. 
Hospitalization is in turn associated with a poorer quality of life and higher costs. 
Patients who experience an ES are more likely to have multiple ES over time. Recent data 
showed that recurrence of ES happens in more than half of all patients with ES, and is more 
common within the first year after the original ES episode (Streitner et al, 2011). 
2.3 Pseudo-storm 
Sometimes multiple recurrent ICD discharges are not associated with ES but are due to 
device malfunctioning. Pseudo-storm is defined as recurrent inappropriate ICD discharges 
over 24 hours. Far from being a minor complication, pseudo-storm is usually physical and 
psychological harmful and potentially lethal. The most common causes of inappropriate 
ICD shock include supraventricular tachycardia with high ventricular response and 
oversening of peaked T waves, myopotentials or electrical noise (Gradaus et al, 2003). 
Recurrent ICD shocks can cause myocardial injury by direct electrocution cell injury and 
by activation of signaling pathways in the molecular cascade of HF, the most important of 
all being adrenergic neurohormonal system. Adrenergic iperactivity may then synergize 
with recurrent ventricular arrhythmias in exacerbating ventricular dysfunction and 
worsening heart failure. In a recent paper on a typical ICD population, Sweeney et al. 
demonstrated that electrical shocks were associated with an increased risk of death 
independently of underlying ventricular arrhythmia (Sweeney et al, 2010). Authors 
esteemed that for every delivered shock, whether appropriate or not, the risk of death 
increases by 20%. On the other hand, no increased risk was associated with anti-
tachycardia pacing (ATP) therapies. Pseudo-storm does not only cause myocardial 
damage, but can deplete a full device battery within hours, potentially leaving the patient 
unprotected from life-threatening arrhythmic events. Although a very rare complication, 
fatal arrhythmias actively caused by pseudo-storm are possible. Messali and coworkers 
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described a patient who, three months after an ICD replacement, received six consecutive 
shocks related to detection of noise interpreted as VF. Unfortunately, the sixth shock 
triggered a true VF, which was not treated due to the end of the therapeutic sequence, and 
which led to the patient’s death (Messali et al, 2004). 
Pseudo-storm should be treated by immediate intervention to suppress ICD shocks. 
Moreover, inappropriate discharges from ICD should be avoided at all cost by an optimal 
device programming. ATP therapy should be preferred over shock in the therapeutic 
sequence, due to its more favorable risk profile. 
3. Clinical presentation of electrical storm 
3.1 Electrical storm in acute myocardial infarction 
Electrical storm, when present, is often the initial manifestation of ischemia and usually 
starts in the first 48 hours of an ST-elevation MI. In that case, pVT is almost always the 
ventricular arrhythmia underlying ES. Ischemia and adrenergic activation increase Purkinje 
cell automaticity, thus letting multiple spontaneous firing. Necrosis, altered myocite 
membrane potential, electrolytic imbalance and even reperfusion damage can all contribute 
to increase dispersion of refractory periods between epicardium and endocardium, thus 
facilitating the propagation of multiple reentry waves. 
ES is a strong negative prognostic factor in acute myocardial infarction. In one study where 
ES was defined as ≥20 VT or VF episodes/day or ≥4 VT/VF episodes/hour, one-week 
incidence of non-sudden death was as high as 50%. The majority of patients who survived 
the acute phase, however, have a prognosis relatively comparable with other ES 
populations. Along with pharmacological therapy, swift and effective reperfusion is crucial 
to end arrhythmic episodes. Retrospective studies and registry data suggest the hypothesis 
that, with modern reperfusion therapy currently available, the incidence of ES could be 
associated with reperfusion time. 
3.2 Electrical storm in heart failure 
Heart failure is an important risk factor for ES. Most of the times, idiopathic dilated 
cardiomyopathy is the structural heart disease underlying heart failure in ES patients, 
followed in prevalence by ischemic cardiomyopathy (Gasparini et al, 2008). Hypertrophic 
cardiomyopathy and valvular cardiomyopathy, albeit uncommon, has been associated with 
heart failure worsening leading to ES (Credner et al, 1998). 
Left ventricular ejection fraction (LVEF) is the most widespread and easy to obtain marker 
of systolic dysfunction and has been used to test the association between heart failure and 
ES. Several studies have found an altered LVEF as an independent risk factor for ES, along 
with older age, chronic renal failure, causative arrhythmia and electrolytic imbalances 
(Exner et al, 2001 and Brigadeau et al, 2006). On the other hand, Streitner and coworkers 
found that a LVEF lower than 30% was not predictive for the initial ES event, but brought a 
2.2-fold increased risk for ES recurrence (Streitner et al, 2011). 
Current evidence suggests that, more than the presence or absence of heart failure by itself, 
it is the progression of heart failure and structural cardiomyopathy the real factor in 
promoting ES and ES recurrence. Therefore, prevention of further systolic function 
deterioration after an initial ES is mandatory and must be achieved through optimization of 
medical and resynchronization therapy. 
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3.3 Electrical storm in patients with congenital pro-arrhythmic diseases 
Genetic arrhythmic syndromes or inherited arrhythmic disorders comprise a group of 
syndromes with unique genetic abnormalities and presentations but with very similar 
clinical outcomes, the most terrifying of which are life-threatening arrhythmias and sudden 
cardiac death. Some of them, such as Brugada syndrome and long QT syndrome, affect 
structural normal hearts, whereas others, such as arrhythmogenic right ventricular 
cardiomyopathy and left ventricular non-compaction affect deeply the myocardial tissue, 
and are included in the cardiomyopathies classification. ES has been described in the 
Brugada syndrome, in the familiar long QT syndrome, in the short-coupled variant of 
torsade de pointes, in catecholaminergic polymorphic ventricular tachycardia, in 
arrhythmogenic right ventricular cardiomyopathy and in myocardial non-compaction. 
Overall, these syndromes are quite rare, being Brugada syndrome the most prevalent with 5 
cases out of 10.000, and association with ES in even rarer. However, patients affected by 
these syndromes are typically young and otherwise completely healthy, making diagnosis 
and treatment of these conditions challenging. 
4. Laboratory and electrical storm 
Although electrolytic imbalances, such as hypokalemia, hyperkalemia and hypomagnesemia 
are a well known risk factors for ventricular arrhythmias and hence ES, many papers report 
that an evident trigger in a majority of patients cannot be identified by laboratory alone. 
Credner et al. underlined the presence of hypokalemia, along with acute coronary syndrome 
and worsening heart failure as potential triggers in 26% of the patients in his case-records 
(Credner et al, 1998). Similarly, Bänsch et al. found hypokalemia as a potential cause of ES in 
20% of their cohort. According to the SHIELD trial, electrolytic imbalance was responsible for 
storm triggering in only 4% of patients (Hohnloser et al, 2006). 
In 2006 for the first time Brigadeau et al. highlighted a possible role of creatinine in 
predicting ES, identifying a storm trigger in 36% of the whole cohort. Among most common 
triggers (such as acute coronary syndrome, high body temperature, hypokalemia or 
hyperkalemia, hyperthyroidism and acute heart failure) chronic renal failure, identified as a 
creatinine clearance lower than 60 ml/min, was independently associated with ES 
occurrence. Thus, this study concluded that the patients with a defibrillator who are likely to 
undergo electrical storm are those who have both low left ventricular ejection fraction and 
chronic renal failure (Brigadeau et al, 2006). In a recent MADIT II chronic kidney disease 
was associated with a 2.1–fold increase in risk for ES in both primary and secondary 
prevention patient (Sesselberg et al., 2007). 
Thyroid disorders (both hypothyroidism and hyperthyroidism) have been suggested as a 
trigger for ES. However, at present there is scarce evidence of an important role of thyroid 
hormones in ventricular arrhythmias pathogenesis. In one case report ES was attributed to 
amiodarone-induced thyrotoxicosis (Marketou et al, 2001). The patient was unresponsive to 
medical therapy and the ES was successfully terminated by thyroidectomy. 
In conclusion, in an ES setting laboratory could play an important role. Electrolytic 
abnormalities such as hypokalemia, hyperkalemia and hypomagnesemia should be 
promptly diagnosed and corrected, as potential triggers of arrhythmic events. High serum 
levels of BNP, creatinine and PCR are valid markers for respectively decompensated heart 
failure, chronic renal insufficiency and pro-inflammatory state, and should be assessed in 
every patients experiencing ES as useful stratification tools. 
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5. Electrical storm therapy 
5.1 Pharmacological therapy  
5.1.1 Amiodarone 
Amiodarone is widely used in the treatment of ventricular arrhythmias. Intravenous 
amiodarone appears to be the most effective agent for ES, and may even suppress 
ventricular tachycardia that recurs despite chronic oral amiodarone therapy. In acute ES, a 
rapid intravenous amiodarone administration (300 mg or 5 mg/kg rapid push followed by 
repeated boluses at half the above doses for breakthrough episodes) blocks fast sodium 
channels in a use-dependent fashion (producing more channel blockade at faster heart 
rates), inhibits norepinephrine release, and blocks L-type calcium channels without 
prolonging ventricular refractoriness. On the other hand, prolonged ventricular refractory 
periods are seen in oral amiodarone therapy over periods ranging from days to weeks. 
Amiodarone has few negative inotropic effects and is safe in patients who have depressed 
systolic function. It is in fact the only anti-arrhythmic drug with solid safety evidences in 
patients with NYHA class III and IV or recently decompensated heart failure. Moreover, the 
incidence of torsades de pointes is low in such patients despite the potential significant 
prolongation of the QT interval. Amiodarone efficacy in terminating ES is approximately 
60%. When compared with placebo in the ARREST trial, amiodarone improved survival to 
hospital admission in patients who had a cardiac arrest that involved VF or pulseless VT 
(Kudenchuk et al, 1999). Amiodarone can be effective even when other agents have been 
ineffective. Levine and colleagues examined 273 hospitalized patients who had electrical 
storm that was refractory to lidocaine, procainamide, and bretylium therapy (Levine et al, 
1996). When amiodarone was given, 46% of the patients survived for 24 hours without 
another episode of VT, and another 12% improved after taking amiodarone plus lidocaine or 
procainamide. Side effects of short-term amiodarone intravenous use are rare. A 
combination of intravenous amiodarone and propranolol improves survival rates and 
should be the mainstay of therapy in acute management of ES. 
Oral amiodarone is effective as adjunctive therapy to prevent recurrent ICD shocks. The 
OPTIC (Optimal Pharmacological Therapy in Implantable Cardioverter) study compared 
amiodarone (200 mg maintenance dose following 6 weeks of loading) plus β-blocker with 
sotalol (240 mg adjusted for renal function) or β-blocker alone (Connolly et al, 2006). 
Appropriate shocks were reduced by amiodarone compared with β-blocker therapy only by 
70%, inappropriate shocks were reduced by 78%, appropriate shocks and ATP were reduced 
by 70%, and all-cause shocks excluding the first 21 days were reduced by 82%. The mean 
number of shocks per year was 4.32 in the beta-blocker only group, 0.93 in the sotalol group, 
and 0.51 in the amiodarone group. Although long-term amiodarone therapy is usually 
successful, substantial side effects include pulmonary fibrosis, hypothyroidism, liver 
toxicity, and corneal deposits. In addition, amiodarone may increase the energy required for 
successful defibrillation, so patients with ICDs should undergo repeated defibrillation 
threshold testing. Patients who have episodes of electrical storm despite amiodarone 
therapy may benefit from β-blockers adjunctive therapy or undergo RF ablation. 
5.1.2 β-blockers 
β-blockers play a key role in the management of electrical storm. Their effects were 
discovered in the 1970s, when they were studied as therapy for acute MI. First evidences 
regarding a possible role as anti-arrhythmic drugs come from canine models (Anderson et 
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al, 1983). All β-blockers increased 6-fold the fibrillation threshold and made the animals less 
susceptible to fibrillation under ischemic and non-ischemic conditions. The improvement 
was greater with the use of more potent β-blockers and with those that antagonized both β1 
and β2 receptors. Although several β-blockers decrease susceptibility to VF, most of the 
studies have focused on propranolol. Propranolol consistently decreases the incidences of 
fatal VF during acute MI and sudden cardiac death after MI (Tsagalou et al, 2005). In 
patients with congestive heart failure, propranolol decreases sympathetic outflow more than 
does metoprolol, perhaps because β2 receptors prevail in failing hearts (Newton et al, 1996). 
The lipophilic nature of propranolol enables active penetration of the central nervous 
system and the blockade of central and prejunctional receptors in addition to peripheral β 
receptors. Propranolol may effectively suppress an electrical storm even when metoprolol 
has failed (Tsagalou et al, 2005). Therefore, propranolol, given at a dose of 0.15 mg/kg 
intravenous bolus over 10 minutes followed by a 3-5 mg dose every 6 hours, is a first line 
therapy in emergency ES setting. Nademanee and coworkers investigated the efficacy of 
sympathetic blockade in electrical storm comparing propranolol, esmolol, and left stellate 
ganglionic blockade to combined lidocaine, procainamide, and bretylium therapy 
(Nademanee et al, 2000). All their patients have experienced a recent MI and more than 20 
episodes of VT within 24 hours or more than 4 episodes per hour. Sympathetic blockade 
provided a marked survival advantage (78% versus 18% at one week, and 67% versus 5% at 
one year). Despite the high doses of propranolol, an increase in heart failure progression 
was not reported in this study, although it is known from previous studies that propranolol 
can exacerbate heart failure in patients with poor systolic function and use in these patients 
should be carefully monitored. The short acting intravenous esmolol may also be used but 
its dosing and titration are somewhat more complicated. Miwa et al. have demonstrated that 
landiolol, an ultra-short acting β1-selective blocker is useful as a life-saving drug for 
amiodarone-resistant ES (Miwa et al, 2010). Landiolol in ES is used intravenously with an 
initial dose of 2.5 µg/kg*min, which can be doubled every 10 minutes if first dose is 
ineffective, up to a maximum dose of 80 µg/kg*min. Landiolol has a shorter plasma half-life 
(4 minutes) than esmolol (9 minutes) or propanolol (2 hours) and higher β1 selectivity. 
These properties suggest that adverse respiratory effects, such as bronchial asma, are less 
likely to develop and to persist with landiolol, which make it more suitable for emergency 
medical care. When amiodarone was ineffective, landiolol inhibited ES in 33 patients (79%) 
at a mean dose of 7.5 µg/kg*min. All patients in whom landiolol was ineffective died of 
arrhythmia. Of the 33 patients in whom landiolol was effective, 25 survived and were 
discharged (60% of all patients). At present, landiolol is not available in most European 
countries and its safety profile in ES still needs to be assessed, making this drug a promising 
alternative to propranolol when amiodarone alone is ineffective. 
5.1.3 Lidocaine 
Intravenous sodium-channel blockers (lidocaine, procainamide) are minimally effective in 
suppressing shock-resistant VT/VF and ES (Credner et al, 1996 and Nademanee et al, 2000). 
Lidocaine binds to fast sodium channels in a use-dependent fashion. Binding increases 
under cellular conditions that are common in ischemic VT, such as reduced pH, faster 
stimulation rate and reduced membrane potential. However, lidocaine has relatively weak 
antiarrhythmic properties outside the ischemic setting: conversion rates from VT to sinus 
rhythm range from 8% to 30%. In one study enrolling patients with out-of-hospital, shock-
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resistant VT or VF, only 12% of those randomized to lidocaine survived to hospital 
admission, versus 23% who received amiodarone. On the basis of this and other findings, 
amiodarone has replaced lidocaine as first line therapy for refractory VT and VF. Actual 
recommendations suggest intravenous lidocaine only in the treatment of polymorphic VT 
associated with acute ischemia. If lidocaine is used, it should be administered as an 
intravenous bolus of 0.5 to 0.75 mg/kg that is repeated every 5 to 10 min as needed. A 
continuous intravenous infusion of 1 to 4 mg/min maintains therapeutic levels. The 
maximum total dose is 3 mg/kg over 1 hr. 
5.1.4 Procainamide 
Procainamide blocks fast sodium channels in a use-dependent fashion and is metabolized to 
N-acetylprocainamide, which in turn blocks potassium channels and accounts for much of 
the antiarrhythmic effect in vivo. When given as a loading dose of 100 mg over 5 min, 
procainamide is a reasonable choice for terminating monomorphic VT. In patients with 
depressed systolic function procainamide can cause hypotension or prolong QRS width by 
more than 50%, either of which would necessitate discontinuation of the drug. Procainamide 
prolongs the QT interval and therefore could cause torsade de pointes. Its use is 
contraindicated in patients with impaired renal function, because N-acetylprocainamide is 
excreted by the kidneys. 
5.1.5 Azimilide 
Azimilide is an experimental class III antiarrhythmic drug that blocks calcium channels and 
prolongs the energy potential and refractory periods. The recently published SHIELD trial 
showed that azimilide is effective and helps to reduce the number of ICD discharges, 
though not mortality (Stefan et al, 2006). A secondary analysis of the SHIELD data found 
that during a prospective one-year follow up azimilide significantly reduced the incidence 
of ES in comparison with placebo. Azimilide could become an alternative for the treatment 
of ES whenever it becomes commercially available. 
5.1.6 Polypharmacological approach 
Optimization of β-blocker therapy is the first important step, particularly when the electrical 
storm is triggered by ischemia or increased sympathetic tone. The next step is initiating anti-
arrhythmic therapy if patient still experiences ES. In the absence of contraindications (such 
as QT lengthening or polymorphic ventricular tachycardia), amiodarone is generally the 
antiarrhythmic drug of choice and has been validated in numerous clinical trials (Kowey et 
al, 1995 and Wood et al, 1995). Most of the time, optimized β-blocker therapy plus 
intravenous amiodarone will control the electrical storm within 24 to 48 hours. This appears 
to be the most effective therapy for electrical storm. If the intravenous combination of 
amiodarone and β-blockers proves inefficacious, the addition of lidocaine is a reasonable 
option. Although controlled data are not available, combination of anti-arrhythmic drug 
allows lower and better tolerated doses of individual drugs, and offers the potential of 
synergistic effects. 
5.1.7 Sedation 
The physical and emotional stress that patients experience in association with electrical 
storm and multiple electrical cardioversions increases adrenergic tone and often perpetuates 
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arrhythmias. All patients who have electrical storm should be sedated. Sedation or general 
anesthesia are needed in resistant cases where repeated shocks or anti-tachicardia 
transthoracic pacing are needed. Short-acting anesthetics such as propofol, benzodiazepines, 
and some agents of general anesthesia have been associated with the conversion and 
suppression of VT (Burjorjee & Milne, 2002). Left stellate ganglion blockade and thoracic 
epidural anesthesia have also suppressed electrical storms that were refractory to multiple 
antiarrhythmic agents and β blockade (Nademanee et al, 2000). These therapeutic 
approaches directly target nerve fibers that innervate the myocardium, and a reduced 
adrenergic tone is most likely responsible for the reported efficacy. Is currently unknown 
whether sedative and anesthetic agents may have direct antiarrhythmic effects. 
5.2 Implantable defibrillators: First-line therapy and first-line diagnostic? 
ES is quite common in ICD recipients. In different studies the incidence of ES in patients 
with an ICD ranges from 10 to 60% when ICDs are implanted for secondary prevention 
(Arya A et al, 2005) and 4% to 7% when ICDs are implanted for primary prevention 
(Sesselberg et al, 2007). A higher incidence of ES in ICD patients is related to an higher 
cardiovascular mortality and morbidity among ICD recipients. As previously said the 
presence of ICD allows the physician to recognize more arrhythmias and the patient to 
survive the arrhythmia and hence manifest more episodes. 
Occurrence of ES after ICD implant has changed over time. A paper from the late 1990s 
reported the peak of incidence of ES between 4 and 5 months after implant (Credner et al, 
1998). On the other hand recent evidences pushed the onset of ES to 26 months after implant 
(Streitner et al, 2011). Total number of episodes varied over time too: as much as 55 mean 
episodes per patient have been reported (Greene et al, 2000), whereas more recent papers 
describe far less VT/VF per single patient (Streitner et al, 2011). Both these findings could be 
explained by changes in antiarrhythmic therapy and ICD technology occurred in this last 
decade which in turn led to fewer total arrhythmic episodes and improved overall prognosis. 
There is a multitude of etiologies of ES in ICD patients: hypokalemia or other electrolytic 
imbalance, drugs (diuretics, b-adrenergic drugs, alcohol), ischemia, medication 
noncompliance and less common causes such as fever or stress (Huang et al, 2005 and Israel 
et al, 2007). The most common cause of ES in ICD patients is exacerbation of heart failure, as 
underlying ischemic or idiopathic dilated cardiomyopathy could progress despite medical 
therapy and arrhythmic prevention. Nevertheless, most ES have no clear etiology and even 
an exhaustive search for acute cause may prove fruitless. 
Clinical presentation can vary dramatically depending on arrhythmias typology 
(monomorphic VT, polymorphic VT or VF) and patient’s characteristics (EF, NYHA class, 
comorbidities). The presence of syncope associated with arrhythmia depends both on 
hemodynamic factors and on ICD settings (mostly shock charging time). The most 
important acute consequence related to ES is hospitalization that is required in more than 
80% of patients, particularly when shocks are delivered (Bansch et al, 2000). ICD patients 
presenting ES have higher morbidity and mortality, hence determination of predictors is 
needed to identify high risk patients. 
Data on risk factors of ES are far from comprehensive or conclusive but most studies 
consider low EF and secondary prevention as major risk factors for developing ES in ICD 
recipients. High NT-proBNP and hs-CRP, history of atrial fibrillation before implant or 
single/dual chamber pacing over CRT are also described as predisposing to ES (Streitner et 
al, 2011). 
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ICD patients who experienced a first ES are also more likely to experience one or more ES 
recurrence. Recurrence rate is as high as 80% within 12 months after the first episode, 
according to Steinert, who described LVEF < 30%, age > 65 years, chronic obstructive 
pulmonary disease and lack of ACE inhibitors therapy as independent predictors of ES 
recurrence (Steinert et al, 2011). 
Most authors report poor prognosis associated whit ES with a risk of death increased from 
1.9 to 17.8 fold. Death rate is usually low during hospitalization and acute episode but 
increases afterward, particularly during the first year after ES. 
Lately, new tools have become available to detect and manage ES in ICD patients. All major 
ICD companies now offer some sort of home or remote monitoring along with their devices. 
Home monitoring offers the physician reports for arrhythmic events, device battery and 
parameters status in real-time. Asymptomatic or lightly symptomatic ES could be then 
promptly recognized and the patient immediately called in for a check-up without the need 
to wait for the next programmed ambulatory visit. Figure 1 shows how an ES looks like on 
auto-generated home monitoring report: the patient experienced 37 arrhythmic episodes in 
less than 24 hours, 36 VT terminated with a shock after ATP sequence was ineffective and 1 
VF episode terminated with ATP. 
Figure 2 shows how EGM can be seen and interpreted via remote monitoring. In this EGM 
VT has been correctly detected and treated by ICD shock. 
5.3 Is cardiac resynchronization therapy useful in preventing electrical storm? 
Cardiac resynchronization therapy (CRT) is a well established therapy for treatment of 
moderate to severe heart failure. Several studies assessed benefits from biventricular pacing 
resulting in prevention of left ventricular remodeling and improvement of hemodynamic, 
ejection fraction, NYHA class, quality of life, morbidity and mortality (Cleeland et al, 2005). 
Effects of CRT on ventricular arrhythmias are less well established. Some evidence suggests 
that pacing itself might cause arrhythmias and some authors reported an increase in 
incidence of atrial fibrillations, ventricular arrhythmias or even electrical storms after 
biventricular pacing (Kantharia et al, 2006). However, currently available large-scale trials 
showed no significant proarrhythmic effects of CRT. On the other hand, there is no strong 
evidence of a direct antiarrhythmic effect of CRT over single or dual chamber pacing either. 
Nordbeck et al. compared incidence of ES in 168 CRT and 561 ICD patients. They found 
significant lower incidence of ES in CRT group (0.6% versus 7%), suggesting that, beside the 
well known hemodynamic improvements, cardiac resynchronization therapy may reduce 
the arrhythmia burden in heart failure patients (Nordbeck et al, 2010). An Italian group 
found a higher incidence of ES (11.3% vs 5.3%) in patients non responder to CRT therapy, 
defined as minor improvement in NYHA class and ejection fraction (Gasparini et al, 2008). 
These data support the hypothesis that CRT may have an indirect antiarrhythmic effect, due 
to factors which are still unclear. Nordbeck suggests that the reduction of arrhythmic 
burden could be due to improvement of cardiac output and ejection fraction from CRT, as 
ejection fraction is a known risk factor for ventricular arrhythmias. Another hypothesis by 
Kowal found some evidences in clinical cases reporting a specific role of cardiac pacing site 
in development or suppression of VT. He hypothesized that the mechanism of arrhythmia 
suppression under biventricular pacing could be ascribed to preexcitation of the area of 
slow conduction responsible for the reentrant arrhythmia (Kowal et al, 2004). 
Nevertheless, electrophysiologic effects of CRT are still poorly understood. Biventricular 
pacing remains a major therapeutic tool in the treatment of heart failure but additional data 
are required to assess its efficacy as antiarrhythmic therapy. 
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Fig. 1. 78 year-old patient with dilated idiopathic cardiomyopathy. In this report the patient 
experienced 37 arrhythmic episodes in less than 24 hours. Physicians can check the report 
directly online in real time, allowing fast diagnosis of ES and, hence, immediate treatment of ES. 
www.intechopen.com
 
Electrical Storm 
 
389 
 
Fig. 2. One of the arrhythmic episodes reported in Fig.1. In this EGM a ventricular 
tachycardia in VT zone starts abruptly following a premature ventricular contraction. Atrio-
venticular dissociation is easily visible. ATP was ineffective whereas 15J delivered shock 
successfully terminated VT. 
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5.4 Specific therapy in congenital pro-arrhythmic diseases 
Although electrical storm associated with Brugada syndrome is exceptional, it is a major 
and life threatening event that requires rapid and effective treatment. In most cases 
presented to date, infusion of isoproterenol (as a 1-2 µg bolus injection followed by 
continuous infusion at 0.15 µg/min, or at a rate of about 0.003 µg/kg/min tritated to result 
in a 20% increase in heart rate), was used to terminate electrical storm. Other cases reported 
intravenous orciprenaline infusion or quinidine as effective in terminating ES. Direct β 
adrenergic stimulation by isoproterenol and orciprenaline increases the L-type calcium 
current, which restores the epicardial action potential dome, normalizes ST segment 
elevations and suppresses ventricular arrhythmias. It should be emphasized that 
orciprenaline or quinidine use as last resort approach in ES is limited to cases of confirmed 
Brugada syndrome, while in the majority of ES associated with ischemic or dilated 
cardiomyopathy, orciprenaline or quinidine application may result in fatal outcome. 
In the congenital long QT syndrome, high dose β-blockers can suppress the occurrence of ES 
and frequent ICD discharges. In refractory cases, left cardiac sympathetic denervation 
results in marked reduction in ES incidence. 
In the ES associated with the short-coupled variant of torsade de pointes ventricular 
tachycardia, verapamil or the combination of verapamil and mexiletine is somewhat 
effective. Intravenous magnesium and overdrive pacing are the treatment of choice for 
drug-induced torsade de pointes. 
Arrhythmogenic right ventricular cardiomyopathy and myocardial non-compaction deeply 
modify heart structure, and ES associated with these conditions is usually resistant to 
medical therapy. Heart transplantation represents nowadays the only viable option for 
terminating recurrent, haemodynamically destabilizing arrhythmias in these patients. 
5.5 Last resource therapies. Radio-frequency ablation and heart transplantation 
5.5.1 Radio-frequency ablation 
Although radiofrequency catheter ablation (CA) has an established role in the treatment of 
recurrent VT, only recently it has been suggested as a method of choice in management of 
ES, especially when pharmacological and ICD therapies fail. The best candidates for CA are 
those ventricular arrhythmias in which the initiating beat or premature ventricular 
contractions morphologically identical to the initiating beat can be localized with 
electroanatomical mapping. In patients affected with ischemic cardiomyopathy the typical 
site of the initiating beat is around the border zone of the scar tissue. The procedure can be 
performed under light anesthesia or deep sedation, according to the hemodynamic state of 
the patient. If the VT is not incessant, a stimulation protocol from right and left ventricle and 
up to three extrastimuli is usually applied to induce clinical VT and determine its 
characteristics. Mapping and ablation is usually performed by an irrigated-tip catheter 
introduced into the right ventricle or left ventricle by direct femoral vein approach or 
retrograde transaortic or transseptal approach, respectively. Electroanatomical mapping is 
nowadays the standard of care, being safe and effective. 
The largest series of patients undergoing CA for refractory ES has been described by 
Carbucicchio and coworkers. Solid electrophysiological evidence of the effective treatment 
of the presenting VT was achieved in 89% of patients, whereas a transient effect of CA 
causing short-term stabilization but ineffective in long-term ES prevention was observed in 
the remaining 11% of patients (Carbucicchio et al, 2008). In this latter group, CA acted only 
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as a temporary bailout, with no impact on ES recurrence. In a recent Czech study RF 
ablation proved effective in suppression of ES in 84% of cases; however, repeated 
procedures were necessary in 1 out of 4 patients (Kozeluhova et al, 2011). Severely 
depressed left ventricular ejection fraction, highly-dilated left ventricle, renal insufficiency, 
and ES recurrence after previous ablation procedure were independently associated with 
adverse outcome within the first 6 months after the procedure. Is it still unclear whether 
inducibility testing of the VT at the end of the study is predictive of mortality and 
arrhythmic recurrences, as currently available data are controversial. 
Successful CA of refractory ES in the absence of a detectable trigger has also been described. 
Schreieck and colleagues reported a case series of 5 ischemic patients with unmappable 
recurrent VTs, in which CA was attempted targeting delayed local potentials guided by 
voltage mapping and pace mapping (Schreieck et al, 2004). These isolated delayed potentials 
are found exclusively in areas of dense scar, making this kind of technique ineffective in 
idiopathic dilated cardiomyopathy. 
On a side note, patients with pseudo-storm due to inappropriate ICD shocks induced by 
atrial tachyarrhythmias can benefit from CA of atrial flutter, atrial fibrillation or even AV 
node ablation. 
5.5.2 Heart transplantation 
Patients with no significant comorbidities except for recurrent ES who experienced no 
improvements from pharmacological, device-related and surgical treatment should be 
considered for cardiac transplantation. Patients with refractory ES associated with a genetic 
arrhythmia syndromes may also be reasonable candidates for heart transplantation as these 
patients are typically young, otherwise healthy individuals with good quality of life and 
prognosis. 
In haemodynamically instable patients, intraaortic balloon pump and cardiac assist devices 
should be used as bridge-to-transplant, as potentially lifesaving. 
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